BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioVisioN AG Grants A Non-Exclusive License On Its DPD-Process To Hoffmann-La Roche (New Jersey) (RHHBY)


10/19/2005 5:10:16 PM

HANNOVER, March 3 /PRNewswire/ -- BioVisioN AG announces that a licensing contract has been closed with F. Hoffmann-La Roche Ltd. (Roche) regarding BioVisioN's patent on the Differential Peptide Display (DPD) technology that allows one to comprehensively visualise the peptides and small proteins (peptidome) within a sample and to analyse changes within the peptidome. Using this technology it is possible to discover a.o. diagnostic biomarkers in human tissue and body fluids. The license allows Roche to use the patent non-exclusively for in-house purposes.

Dr. Sven Rohmann, CEO of BioVisioN, stated, "It is a confirmation of the value of our efforts that such a renowned company as Roche wants to use our technology for its research."

BioVisioN AG is an independent biotech company in Hannover, Germany. Founded in 1997 by Dr. Peter Schulz-Knappe, Dr. Michael Schrader, Prof. Dr. Dr. Wolf-Georg Forssmann and Dr. Hans-Georg Opitz, it now has 45 employees. The most important partners hitherto are Roche Diagnostics GmbH (Germany), Novo Nordisk A/S (Denmark), AstraZeneca Ltd. (UK), Applied Biosystems (USA), Matrix Science Ltd. (UK) and the Swiss Institute for Research in Allergy and Asthma.

BioVisioN AG specializes in the identification of disease-relevant peptides and proteins using its proprietary Peptidomics(TM) technologies in order to discover new diagnostic markers, or biomarkers and therapeutic leads and targets. Apart from research collaborations, BioVisioN provides access to its technology also in fee-for-service contracts as a Biological Research Organisation.

Further information can be found on our new website http://www.biovision-discovery.de/

BioVisioN AG

CONTACT: Dr. Rainer Voegeli, Head of Business Development for BioVisioNAG, +49-0-511-538-896-0, Fax - +49-0-511-538-896-66,info@biovision-discovery.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES